Related Experiment Video

Updated: Aug 14, 2026

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

RNA interference for treating haematological malignancies

Elizabeth O Hexner1, Alan M Gewirtz

  • 1Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Expert Opinion on Biological Therapy
|December 2, 2005
PubMed

Insights

RNA interference (RNAi) offers a promising gene silencing therapy for blood cancers. Overcoming challenges like immune response and delivery is key for successful human trials.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Hematology

Background:

  • RNA interference (RNAi) is a gene silencing mechanism with therapeutic potential.
  • RNAi is gene-specific, potent, and minimally toxic, making it suitable for treating hematological malignancies.

Purpose of the Study:

  • To review the current state of RNA interference (RNAi) for treating hematological malignancies.
  • To discuss the challenges and progress in translating RNAi technology to human clinical trials.

Main Methods:

  • Review of existing laboratory and translational research on RNAi.
  • Analysis of fundamental mechanisms and clinical application hurdles.

Main Results:

  • RNAi demonstrates significant promise for treating blood cancers due to its specificity and potency.
  • Key challenges for human trials include managing immune responses, target selection, molecule design, and delivery/safety.

Conclusions:

  • Translational research is actively addressing the hurdles for clinical RNAi application in hematological malignancies.
  • Continued research is essential to fully realize the therapeutic potential of RNAi in treating blood cancers.

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...